How to Get Prolia (Denosumab) in West Virginia

West Virginia Permits Telehealth Prescribing of Denosumab

Telehealth is a valid pathway to a denosumab prescription in West Virginia. The state's Board of Medicine and Board of Osteopathic Medicine both recognize synchronous audio-video consultations as sufficient to establish a provider-patient relationship, which means a clinician licensed in WV can evaluate bone density results, review labs, and prescribe Prolia without an in-person visit.

How a Telehealth Visit Works for Prolia

A typical telehealth consultation for denosumab takes 15 to 25 minutes. The provider reviews your DXA scan (T-score of -2.5 or below at the femoral neck or lumbar spine, or a FRAX 10-year hip fracture probability of 3% or higher), confirms adequate calcium and vitamin D levels, and checks renal function. If you meet prescribing criteria, the clinician transmits the prescription electronically to a specialty pharmacy or arranges administration at a local infusion clinic.

Which Providers Offer Telehealth for Bone Health in WV

Endocrinologists and rheumatologists affiliated with WVU Medicine, CAMC, and Marshall Health all offer virtual visits. National telehealth platforms licensed in West Virginia can also prescribe denosumab when supported by appropriate imaging and laboratory documentation. HealthRX connects patients with board-certified providers who can evaluate osteoporosis and prescribe biologic therapies including denosumab via telehealth.

Limitations of the Telehealth Route

Because Prolia is a subcutaneous injection administered every 6 months, you still need a physical location for the injection itself. Options include your PCP's office, an infusion center, or a home health nurse. The prescription itself, however, requires no in-person visit.

Who Can Prescribe Prolia in West Virginia

West Virginia grants prescriptive authority for denosumab to physicians (MD and DO), nurse practitioners, and physician assistants. NPs in WV practice under a collaborative agreement for the first three years after licensure, after which they may practice independently per WV Code §30-7-15a 1.

Specialist vs. Primary Care Prescribing

Most Prolia prescriptions originate from endocrinology or rheumatology, but any provider with prescriptive authority can write the order. A 2021 analysis in the Journal of Bone and Mineral Research found that 34% of denosumab prescriptions nationally came from primary care physicians [2]. In rural West Virginia, where specialist access is limited across 44 of 55 counties classified as medically underserved, PCP prescribing is common.

What Qualifications to Look For

Seek a provider who routinely manages osteoporosis and understands the rebound vertebral fracture risk documented after Prolia discontinuation. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend that any provider prescribing denosumab have a clear transition plan (typically to a bisphosphonate) if therapy is stopped 3.

Required Labs Before Starting Denosumab

Prolia's FDA label mandates correction of hypocalcemia before initiation 4. A baseline lab panel is non-negotiable.

The Standard Pre-Prolia Lab Panel

• Serum calcium (corrected for albumin)
• 25-hydroxyvitamin D (target ≥30 ng/mL)
• Estimated glomerular filtration rate (eGFR)
• Complete metabolic panel (CMP)
• Phosphorus (optional but recommended by AACE)

Why Vitamin D Matters Specifically

Patients with 25-OH vitamin D below 20 ng/mL face a significantly higher risk of symptomatic hypocalcemia post-injection. The FREEDOM extension study documented that adequate vitamin D supplementation (≥800 IU daily) during denosumab therapy reduced hypocalcemia incidence to under 2% 5. West Virginia has high rates of vitamin D insufficiency due to geographic latitude and indoor occupation patterns in coal and chemical industries, making this lab particularly relevant for WV patients.

DXA Scan Requirements

A dual-energy X-ray absorptiometry (DXA) scan confirming a T-score of -2.5 or below, or evidence of a fragility fracture, is the diagnostic foundation. DXA facilities exist in Charleston, Morgantown, Huntington, Parkersburg, and Wheeling. Mobile DXA units also serve rural counties on rotating schedules.

Insurance and Cost Pathways in West Virginia

Prolia's wholesale acquisition cost is approximately $1,860 per injection (list price, 2025). Out-of-pocket cost depends entirely on insurance status.

Commercial Insurance

Most commercial plans in West Virginia (including those sold on the ACA marketplace) cover Prolia with prior authorization. The prior auth process typically requires documentation of a DXA T-score ≤ -2.5, or T-score ≤ -1.0 with a prior fragility fracture, plus evidence that the patient has tried or is intolerant to oral bisphosphonates (alendronate or risedronate).

West Virginia Medicaid: Not Covered

West Virginia Medicaid does not cover Prolia for the osteoporosis indication as of 2026. Patients on Medicaid must pursue alternatives: oral bisphosphonates (alendronate, $4/month generic), IV zoledronic acid (covered as a medical benefit), or Amgen's patient assistance program.

Medicare Part B

Prolia administered in a physician's office is covered under Medicare Part B as a medical benefit, not a pharmacy benefit. The patient pays 20% coinsurance after the Part B deductible ($257 in 2026). For a $1,860 injection, that equals roughly $372 out of pocket every six months, though supplemental Medigap policies may reduce this to zero.

Amgen's Prolia Patient Assistance

Amgen offers the "Amgen Safety Net Foundation" program for uninsured or underinsured patients. Eligibility requires household income at or below 300% of the federal poverty level. Approved patients receive Prolia at no cost. Application processing takes 5 to 10 business days.

Pharmacy and Administration Options in West Virginia

Denosumab is not a self-administered drug for most patients. It requires a subcutaneous injection in the upper arm, thigh, or abdomen, typically delivered in a clinical setting.

Specialty Pharmacies

Prolia is distributed through specialty pharmacies. In West Virginia, Fruth Pharmacy (specialty division), Omnicare, and national chains like CVS Specialty, Optum Specialty, and Accredo all ship to WV addresses. The medication arrives in a prefilled syringe requiring refrigeration (2°C to 8°C).

503A Compounding Pharmacies

West Virginia licenses 503A compounding pharmacies that can prepare patient-specific prescriptions. While denosumab itself is a biologic that cannot be traditionally compounded, 503A pharmacies may handle adjunctive preparations (calcium/vitamin D formulations, for example) and serve as dispensing intermediaries for specialty products.

Administration Sites

The injection takes under 60 seconds. Options for administration in WV include:

• Primary care offices (most common)
• Rheumatology or endocrinology clinics
• Hospital outpatient infusion centers (CAMC, WVU Ruby Memorial, St. Mary's)
• Home health nursing services (available in all 55 counties through WV Home Health agencies)

The Prior Authorization Process in West Virginia

Prior authorization is required by nearly all commercial payers and Medicare Advantage plans in West Virginia before Prolia can be dispensed or administered.

Standard Documentation Requirements

Insurers in WV typically require:

1. DXA scan report with T-scores at lumbar spine, femoral neck, and total hip
2. Documentation of fracture history (if applicable)
3. Trial or contraindication to oral bisphosphonates (usually 3 to 6 months of alendronate or risedronate, or documented GI intolerance/esophageal disorder)
4. Current labs showing corrected calcium within normal range
5. Provider's clinical rationale letter

Timeline for Approval

Standard prior authorization decisions in West Virginia must be rendered within 15 calendar days for non-urgent requests per WV Insurance Commission regulations. Urgent requests require a decision within 72 hours. Most denosumab PAs are processed in 3 to 7 business days.

If Denied: The Appeals Process

If your PA is denied, West Virginia law (WV Code §33-25D-2) guarantees the right to an internal appeal within 30 days of the denial notice. If the internal appeal fails, you may request an external review by an independent review organization within 4 months. Success rates for osteoporosis biologic appeals exceed 60% nationally when supported by guideline-concordant documentation 6.

Clinical Evidence Supporting Denosumab Access

The FREEDOM trial (N=7,868) randomized postmenopausal women with osteoporosis to denosumab 60 mg SC every 6 months versus placebo for 36 months. Denosumab reduced the risk of new vertebral fractures by 68% (RR 0.32, 95% CI 0.26-0.41), hip fractures by 40%, and nonvertebral fractures by 20% 7.

Long-Term Extension Data

The FREEDOM extension followed participants for up to 10 years of continuous denosumab therapy. Fracture incidence remained low, with vertebral fracture rates of 0.90% to 1.86% per year through year 10. Bone mineral density continued to increase without plateau, reaching cumulative gains of 21.7% at the lumbar spine and 9.2% at the total hip 8.

The Rebound Fracture Concern

Discontinuation of denosumab without transition to an alternative antiresorptive leads to rapid bone loss and a documented spike in vertebral fractures. A 2017 analysis documented multiple vertebral fractures in 5% to 10% of patients within 7 to 12 months of stopping therapy 9. This makes access continuity in West Virginia especially important for patients who begin therapy.

"Once a patient starts denosumab, maintaining access to ongoing doses is a clinical priority. Interruption is not benign." This language aligns with the 2020 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 3.

Timeline: From Consultation to First Injection

For West Virginia patients starting from scratch, the typical path takes 2 to 4 weeks.

Week-by-Week Breakdown

Days 1-3: Schedule telehealth or in-person consultation. Obtain lab orders.

Days 3-7: Complete labs (serum calcium, vitamin D, CMP, eGFR). If DXA is not already on file, schedule one (wait times vary from same-week in Charleston to 2-3 weeks in rural counties).

Days 7-14: Provider reviews results, submits prior authorization if required.

Days 14-21: PA approval received. Specialty pharmacy ships medication to administering provider's office.

Days 21-28: First injection administered.

Patients with recent DXA results and labs already in hand may compress this timeline to 7 to 10 days.

Transferring a Prolia Prescription to West Virginia

Patients relocating to WV from another state can transfer their denosumab prescription. The process requires:

1. Your new WV-licensed provider to review your records and accept the prescription
2. Prior authorization resubmission under your new insurance (if the plan changed)
3. Specialty pharmacy transfer or new enrollment

Because Prolia is dosed every 6 months, timing the transfer between doses is ideal. Missing a dose by more than 4 weeks increases rebound fracture risk per the AACE guidelines 3.